No­var­tis is send­ing 500 jobs to the scrap heap while adding 350 ‘high-tech’ po­si­tions for growth

No­var­tis is tak­ing out the ax again in its on­go­ing glob­al re­or­ga­ni­za­tion, cut­ting in­to its R&D group while mak­ing room for hun­dreds of new hires. Fol­low­ing an over­haul that was fo­cused on the US and Asia last year, it’s the Basel cam­pus that’s get­ting a makeover now.

Up to 500 jobs in No­var­tis’ drug de­vel­op­ment, “tra­di­tion­al” man­u­fac­tur­ing and co­or­di­na­tion group are be­ing scrapped, with the staffers ei­ther be­ing laid off, re­tir­ing ear­ly or mov­ing to oth­er lo­ca­tions. Mov­ing in­to the com­pa­ny will be 350 new em­ploy­ees for “high-tech” po­si­tions in Switzer­land, al­so for drug de­vel­op­ment as well as “in­no­v­a­tive” bi­o­log­ics man­u­fac­tur­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.